Synapse - Robert Motzer

Results (1247)

Use of a large language model (LLM) for pan-cancer automated detection of anti-cancer therapy toxicities and translational toxicity research

Meeting Abstract

Bakouny, Z.; Ahmed, N.; Fong, C.; Rahman, A.; Perea-Chamblee, T.; Pichotta, K.; Waters, M.; Fu, C.; Jeng, M. Y.; Lee, M.; more...
Journal of Clinical Oncology (2025)

Fulltext@MSK | Save

KEAP1 mutated renal cell carcinoma (RCC): Characterization of an emerging molecularly defined RCC subtype

Meeting Abstract

Carlo, M.; Chen, Y. B.; Knezevic, A.; Zong, G.; Bakouny, Z.; Kemel, Y.; Latham, A.; Liu, Y. L.; Shah, N. J.; Feldman, D. R.; more...
Journal of Clinical Oncology (2025)

Fulltext@MSK | Save

Efficacy of second line (2L) treatment with tivozanib (Tivo) as monotherapy or with nivolumab (Nivo) in patients (pts) with metastatic renal cell carcinoma (mRCC) previously treated with an immune checkpoint inhibitor (ICI) combination of ipilimumab (Ipi)/Nivo or vascular endothelial growth factor receptor-tyrosine kinase inhibitor (VEGFR-TKI)/ICI in the phase 3 TiNivo-2 study

Meeting Abstract

Chehrazi-Raffle, A.; Motzer, Robert J.; Beckermann, K.; Barthelemy, P.; Iacovelli, R.; Emambux, S.; Molina Cerrillomd, J.; Garmezy, B.; Barata, P. C.; McKay, R. R.; more...
Journal of Clinical Oncology (2025)

Fulltext@MSK | Save

Clear and non-clear cell renal cell carcinomas and the ability to engage in oxidative phosphorylation

Meeting Abstract

Bakouny, Z.; Boscenco, S.; Cui, R.; Ryu, K.; Kotecha, R. R.; Carlo, M.; Voss, M. H.; Hakimi, A. A.; Motzer, R. J.; Gammage, P. A.; more...
Journal of Clinical Oncology (2025)

Fulltext@MSK | Save

Oncologic outcomes of retroperitoneal lymph node dissection following first-line chemotherapy for metastatic non-seminomatous germ-cell tumors

Journal Article

Matulewicz, R. S.; Baky, F.; Liso, N.; Williams, B. M.; Porwal, S.; Assel, M.; Carver, B. S.; Bajorin, D. F.; Motzer, R. J.; Bosl, G. J.; more...
Annals of Oncology (2025)

Fulltext@MSK | Save

Health-related quality-of-life profile and clinical outcomes in first-line advanced renal cell carcinoma: A modeling analysis based on the CheckMate 9ER study

Journal Article

Cella, D.; Derosa, M.; Floden, L.; Giles, R. H.; Lothgren, M.; Ogareva, A.; Powles, T.; Purnajo, I.; Choueiri, T. K.; Bergerot, C.; more...
ESMO Open (2025)

Fulltext@MSK | Save

Real-world treatment patterns and clinical outcomes among patients with metastatic renal cell carcinoma post-immune-oncology and vascular endothelial growth factor receptor targeted therapies

Journal Article

Shah, N. J.; Sura, S.; Shinde, R.; Shi, J.; Bupathi, M.; Vickery, D.; Motzer, R. J.
Cancers (2025)

Fulltext@MSK | Save

INTerpath-004: A phase 2, randomized, double-blind study of adjuvant pembrolizumab (pembro) with V940 (mRNA-4157) or placebo for renal cell carcinoma (RCC)

Meeting Abstract

Motzer, R. J.; Braun, D. A.; Powles, T.; Gurney, H.; Fong, L.; George, D. J.; Haas, N. B.; McDermott, D. F.; Shuch, B. M.; Meehan, R.; more...
Journal of Clinical Oncology (2025)

Fulltext@MSK | Save

STARLITE 2: Phase 2 study of nivolumab plus (177)lutetium-labeled anti-carbonic anhydrase IX (CAIX) monoclonal antibody girentuximab ((177)Lu-girentuximab) in patients with advanced clear cell renal cell carcinoma (ccRCC)

Meeting Abstract

Feldman, D. R.; Motzer, R. J.; Knezevic, A.; Voss, M. H.; Lyashchenko, S. K.; Park, H.; Larson, S. M.; Pandit-Taskar, N.
Journal of Clinical Oncology (2025)

Fulltext@MSK | Save

A phase 1b, open-label, safety, tolerability, and efficacy study of HC-7366 in combination with belzutifan in patients with advanced or metastatic renal cell carcinoma (NCT06234605)

Meeting Abstract

Shah, N. J.; Bupathi, M.; Garmezy, B.; McKay, R. R.; Ornstein, M. C.; Figlin, R. A.; Picus, J.; Rank, B. H.; Barata, P. C.; Hammers, H. J.; more...
Journal of Clinical Oncology (2025)

Fulltext@MSK | Save